

MONTHLY MEDICATION SAFETY UPDATE

Information for health professionals in NSW public health organisations

This is a summary of medication safety and supply related issues affecting NSW public health facilities in **August 2026**. View medication safety and supply updates on our [website](#).

Medication Safety and Supply Summary

78	Safety/supply issues requiring investigation by the CEC
13	Reported to the frontline due to safety risk requiring local mitigation
0	Formal safety communication developed
3	Previous issues resolved on CEC Medication Safety Updates table

Safety Broadcasts released

Nil

Medications reported on CEC Medication Safety Updates table this month:

- Acetazolamide 500 mg injection
- Avatrombopag 20 mg tablets
- Bromocriptine 2.5 mg tablets
- Cyclophosphamide and ifosfamide injections
- Dinoprostone vaginal gel
- Enoxaparin (Clexane) injections
- Fludarabine phosphate injection vials
- Hydralazine 20 mg injection
- Mercaptamine (cysteamine bitartrate) 150 mg capsules
- Olanzapine depot injections
- Pegfilgrastim 6 mg/0.6 mL
- Promethazine 50 mg/2 mL injection ampoule
- Terbutaline 0.5 mg/mL injection ampoules

Therapeutic Goods Administration (TGA) updates:

- *Product Information safety updates:* [August 2026](#)
- *Safety alerts and updates:*
 - [Melanotan II tanning peptide products found to be inconsistently dosed](#)
 - [CAROTONE skin-brightening products found to contain undeclared prescription-only medicine](#)
- *Medicine shortage alerts*
 - [Substitutions available for shortage of Dapsone 25 mg tablets](#)

CEC updates:

- The NSW standardised continuous infusion concentrations support the safe, consistent, and efficient prescribing, preparation, and administration of parenteral continuous infusions. Information surrounding the concentrations will be hosted on the CEC website. The **adult** standardised continuous infusion concentrations are now available [here](#), with the paediatric and neonatal concentrations to follow.
- Factsheet [Disruption to supply – Promethazine 50 mg/2 mL injection ampoule](#) has been published on the CEC website. This fact sheet outlines the current supply disruption affecting the Australian-registered promethazine injection product and highlights key differences and safety considerations associated with international alternatives approved for use during the shortage.
- Following the formal transition of the platform and register name to the **Register of Emergency and Life-saving Medicines (REALM)**, the LSDR URL has now been decommissioned. NSW Health services should ensure that any links to the former LSDR URL within intranet pages, local policies, clinical guidelines, and other resources are updated to the [current URL](#).
- Arginine and sodium benzoate have been endorsed for inclusion on REALM for the treatment of acute hyperammonemia due to inborn errors of metabolism a following change request submission. Further information on these medicines is available in the Decision and Change Summary on the [REALM Updates and Resources page](#).

Contact:

CEC-MedicationSafety@health.nsw.gov.au